Objective: Ovarian cancer is one of the most deadliest cancer and is highly resistant to conventional chemotherapy, which raises a need for new therapeutic paradigm. In the present study, we investigated the anti-cancer effects of CWP232228, a highly potent inhibitor of Β-catenin signaling via antagonizing binding of Β-catenin to T-cell factor (TCF). Methods: The ovarian cancer cell lines were treated with different concentrations of CWP 232228. The cell viability and cell cycle distribution was measured by MTT and flow cytometric analysis. The transcriptional change of mRNA was examined by RT-PCR. The induction of growth inhibitory effect was measured by cell migration assay, DNA fragmentation assay and western blot analysis Results: First, we found that the cytotoxic effects of CWP232228 is positively dependent on the expression levels of Β-catenin. We also found that CWP232228 potently inhibited both anchorage-dependent and -independent growth of ovarian cancer cells. Next we showed that CWP232228 markedly increased apoptosis via western and FACS analyses In addition to growth inhibitory effect, we discovered that CWP232228 attenuated a collective cell migration. Moreover, CWP232228 effectively inhibited the stemness of ovarian cancer cells. CWP232228 prevented the sphere forming ability and self-renewal activity of ovarian cancer stem like cells (CSCs). Conclusion: These results clearly suggested the anti-tumor effects of CWP232228 in ovarian cancer cells with high expression level of Β-catenin. Taken together, our findings offers a possible therapeutic use of CWP232228 as a precision medicine agent that targets ovarian cancer with high expression level of Β -catenin.